Science Corporation Raises $400 Million Series D at $3.5 Billion Valuation
Science Corporation, founded by former Neuralink president Max Hodak, has raised a $400 million Series D round at a $3.5 billion valuation to scale its anti-blindness chip and advance a bio-hybrid brain interface.
By The Daily Circuit AI Desk (automated, AI-generated)
2 min read
AI-generated image (flux-1-schnell), not a photograph of the events described.
Key facts
- Science Corporation raised a $400 million Series D funding round.[1]
- Investors valued the company at $3.5 billion, according to a person familiar with the deal.[1]
- The company was founded by Max Hodak in 2021; Hodak is a former president of Neuralink.[1]
- Investors included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.[1]
- PRIMA, Science’s first product, is a wearable and implantable chip for age-related macular degeneration.[1]
- PRIMA is approved in Europe and available in Germany.[1]
- The device is being trialled for Stargardt’s disease.[1]
- Science plans to seek US approval via the FDA’s Humanitarian Device Exemption.[1]
Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, has raised a $400 million Series D funding round. Investors in the round valued the company at $3.5 billion, according to a person familiar with the deal who spoke to TechCrunch. The company disclosed the funding in a blog post. [1]
Backers in the Series D included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. [1] The capital will be used to scale up Science’s anti-blindness business. [1]
Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. [1] The device is approved in Europe and is available in Germany. [1] It is also being trialled for new conditions. [1] Speaking onstage at TechCrunch Disrupt, Hodak announced that PRIMA is now being trialled for patients with Stargardt’s disease, another condition that causes blindness. [1]
The company intends to bring PRIMA to the United States through the Food and Drug Administration’s Humanitarian Device Exemption. [1] This regulatory pathway permits experimental medical technology to be used to treat rare conditions. [1] Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to allow the company to seek approval for use of the device in the US. [1]
While vision restoration is the current commercial focus, Science’s founding purpose is broader: connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. [1] The company is currently designing initial human trials of that device with Murat Günel, a neurosurgery professor at Yale. [1] Günel told TechCrunch that the technology could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses. [1]
Hodak has pursued biotechnology since talking his way into a graduate neuroscience lab as a college student. [1] He co-founded Science to leverage new technologies to understand and interact with the brain. [1]
The company’s blog post announced the $400 million round. The $3.5 billion valuation was reported by TechCrunch based on information from a person familiar with the deal. [1] The source did not provide a timeline for the initial human trials of the bio-hybrid sensor. [1] Any application to Parkinson’s disease remains a potential use described by Günel rather than a confirmed clinical programme. [1]
This article was generated by The Daily Circuit’s automated desk and is disclosed to readers as AI-generated. All factual claims are drawn from TechCrunch reporting. [1]
Context
The funding round values Science Corporation at $3.5 billion and adds to recent private-market activity in brain-technology and medical devices. The company’s regulatory strategy for PRIMA relies on the FDA’s Humanitarian Device Exemption, a pathway intended for rare conditions.
Why it matters
The round signals continued investor confidence in neurotechnology and implantable medical devices, even as Science transitions from its first approved product toward earlier-stage brain-interface research.
What could happen next
AI-generated analysis based on the sources below. Not a forecast or recommendation.
If the FDA grants clearance under the Humanitarian Device Exemption, PRIMA could become available to US patients with advanced macular degeneration in both eyes. The longer-term bio-hybrid sensor work remains preclinical, with human trials still being designed.
Risks and open questions
The $3.5 billion valuation has not been confirmed by the company in its public blog post and rests on a single person familiar with the deal. The bio-hybrid brain interface has no disclosed trial timeline, and its potential application to Parkinson’s disease is described as a possibility rather than a confirmed programme.
Sources
- 1.TechCrunch (primary source): Science Corporation’s brain tech is worth $3.5 billion after new funding, 17 November 2026
How this article was produced. This story was researched and written by an automated system using the open model nvidia/nemotron-3.5-super-vl (via OpenRouter), working only from the sources listed above. Automated checks verified that every citation, quote and figure matches those sources before publication. It was not written by a human reporter. Editorial policy · Report an error
- Science Corporation
- Max Hodak
- Neuralink
- PRIMA
- brain-computer interface
- Series D
Related stories
Spotify Introduces Artist Profile Protection Tool to Tackle Deepfakes and Misattributed Music
Spotify is launching its Artist Profile Protection tool globally to help creators combat deepfakes, impersonation, and metadata errors on their streaming profiles.
2 min read
Nvidia Establishes National Security Board Committee Following Jensen Huang Resignation
Nvidia has formed a board-level committee to oversee national security policies and export compliance following the resignation of CEO Jensen Huang.
3 min read
United Airlines Blocks AI Agents From Booking Flights and Managing Reservations
United Airlines has restricted AI agents from accessing its digital platforms to book flights and manage reservations, citing cybersecurity concerns and regulatory compliance.
2 min read
Carnegie Mellon Researcher Develops OATs Virtual Pet Gadgets for Everyday Objects
A Carnegie Mellon University PhD student has introduced OATs, tiny E Ink micro-agent AI avatars that attach to household items to encourage better habits through expressive digital pets.
2 min read